ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.62 USD | +0.84% |
|
+2.40% | +15.25% |
| 08/05 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| 08/05 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.38% | 9 M€ | -4.31% | - | |
| 0.99% | 0 M€ | +2.15% | ||
| 0.77% | 0 M€ | +5.55% | - | |
| 0.43% | 0 M€ | +3.32% | ||
| 0.38% | 0 M€ | 0.00% | - | |
| 0.32% | 0 M€ | 0.00% | - | |
| 0.15% | 0 M€ | +18.09% | - | |
| 0.09% | 0 M€ | +3.88% | - | |
| 0.04% | 0 M€ | +9.11% | - | |
| 0.03% | 15 M€ | -1.62% | - | |
| 0.03% | 2 M€ | +3.16% | - | |
| 0.02% | 0 M€ | +0.48% | - | |
| 0.01% | 0 M€ | +2.89% | - | |
| 4.53% | 0 M€ | +4.75% | - |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
154.3
USD
Average target price
166.5
USD
Spread / Average Target
+7.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +8.31% | 204B | |
| -7.57% | 198B | |
| +8.62% | 168B | |
| +4.59% | 125B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
- Funds and ETFs AstraZeneca PLC